Suppr超能文献

工作场所干预措施以降低医疗机构外 SARS-CoV-2 感染的风险。

Workplace interventions to reduce the risk of SARS-CoV-2 infection outside of healthcare settings.

机构信息

Clinical Research Center, Fundación Valle del Lili, Cali, Colombia.

Cochrane Austria, Department for Evidence-based Medicine and Evaluation, Danube University Krems, Krems, Austria.

出版信息

Cochrane Database Syst Rev. 2022 May 6;5(5):CD015112. doi: 10.1002/14651858.CD015112.pub2.

Abstract

BACKGROUND

Although many people infected with SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) experience no or mild symptoms, some individuals can develop severe illness and may die, particularly older people and those with underlying medical problems. Providing evidence-based interventions to prevent SARS-CoV-2 infection has become more urgent with the spread of more infectious SARS-CoV-2 variants of concern (VoC), and the potential psychological toll imposed by the coronavirus disease 2019 (COVID-19) pandemic.   Controlling exposures to occupational hazards is the fundamental method of protecting workers. When it comes to the transmission of viruses, such as SARS-CoV-2, workplaces should first consider control measures that can potentially have the most significant impact. According to the hierarchy of controls, one should first consider elimination (and substitution), then engineering controls, administrative controls, and lastly, personal protective equipment (PPE).

OBJECTIVES

To assess the benefits and harms of interventions in non-healthcare-related workplaces to reduce the risk of SARS-CoV-2 infection relative to other interventions, or no intervention.

SEARCH METHODS

We searched MEDLINE, Embase, Web of Science, Cochrane COVID-19 Study Register, the Canadian Centre for Occupational Health and Safety (CCOHS), Clinicaltrials.gov, and the International Clinical Trials Registry Platform to 14 September 2021. We will conduct an update of this review in six months.

SELECTION CRITERIA

We included randomised control trials (RCT) and planned to include non-randomised studies of interventions. We included adult workers, both those who come into close contact with clients or customers (e.g. public-facing employees, such as cashiers or taxi drivers), and those who do not, but who could be infected by co-workers. We excluded studies involving healthcare workers. We included any intervention to prevent or reduce workers' exposure to SARS-CoV-2 in the workplace, defining categories of intervention according to the hierarchy of hazard controls, i.e. elimination; engineering controls; administrative controls; personal protective equipment.

DATA COLLECTION AND ANALYSIS

We used standard Cochrane methods. Our primary outcomes were incidence rate of SARS-CoV-2 infection (or other respiratory viruses), SARS-CoV-2-related mortality, adverse events, and absenteeism from work. Our secondary outcomes were all-cause mortality, quality of life, hospitalisation, and uptake, acceptability, or adherence to strategies. We used the Cochrane RoB 2 tool to assess the risk of bias, and GRADE methods to assess the certainty of evidence for each outcome.

MAIN RESULTS

Elimination of exposure interventions We included one study examining an intervention that focused on elimination of hazards. This study is an open-label, cluster-randomised, non-inferiority trial, conducted in England in 2021. The study compared standard 10-day self-isolation after contact with an infected person to a new strategy of daily rapid antigen testing and staying at work if the test is negative (test-based attendance). The trialists hypothesised that this would lead to a similar rate of infections, but lower COVID-related absence. Staff (N = 11,798) working at 76 schools were assigned to standard isolation, and staff (N = 12,229) at 86 schools to the test-based attendance strategy.  The results between test-based attendance and standard 10-day self-isolation were inconclusive for the rate of symptomatic PCR-positive SARS-COV-2 infection rate ratio ((RR) 1.28, 95% confidence interval (CI) 0.74 to 2.21; 1 study, very low-certainty evidence)). The results between test-based attendance and standard 10-day self-isolation were inconclusive for the rate of any PCR-positive SARS-COV-2 infection (RR 1.35, 95% CI 0.82 to 2.21; 1 study, very low-certainty evidence). COVID-related absenteeism rates were 3704 absence days in 566,502 days-at-risk (6.5 per 1000 days at risk) in the control group and 2932 per 539,805 days-at-risk (5.4 per 1000 days at risk) in the intervention group (RR 0.83; 95% CI 0.55 to 1.25). The certainty of the evidence was downgraded to low, due to imprecision. Uptake of the intervention was 71 % in the intervention group, but not reported for the control intervention.  The trial did not measure other outcomes, SARS-CoV-2-related mortality, adverse events, all-cause mortality, quality of life, and hospitalisation. We found one ongoing RCT about screening in schools, using elimination of hazard strategies. Personal protective equipment We found one ongoing non-randomised study on the effects of closed face shields to prevent COVID-19 transmission. Other intervention categories We did not find studies in the other intervention categories.

AUTHORS' CONCLUSIONS: We are uncertain whether a test-based attendance policy affects rates of PCR-postive SARS-CoV-2 infection (any infection; symptomatic infection) compared to standard 10-day self-isolation amongst school and college staff. Test-based attendance policy may result in little to no difference in absence rates compared to standard 10-day self-isolation. As a large part of the population is exposed in the case of a pandemic, an apparently small relative effect that would not be worthwhile from the individual perspective may still affect many people, and thus, become an important absolute effect from the enterprise or societal perspective.  The included study did not report on any other primary outcomes of our review, i.e. SARS-CoV-2-related mortality and adverse events. No completed studies were identified on any other interventions specified in this review, but two eligible studies are ongoing. More controlled studies are needed on testing and isolation strategies, and working from home, as these have important implications for work organisations.

摘要

背景

尽管许多感染严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)的人没有或仅有轻微症状,但有些人会患重病甚至死亡,尤其是老年人和有基础疾病的人。随着更具传染性的 SARS-CoV-2 变体关注(VOC)的传播,以及 2019 年冠状病毒病(COVID-19)大流行带来的潜在心理影响,为预防 SARS-CoV-2 感染提供循证干预措施变得更加紧迫。控制职业危害暴露是保护工人的根本方法。当涉及到病毒(如 SARS-CoV-2)的传播时,工作场所首先应考虑可能产生最大影响的控制措施。根据控制层次,首先应考虑消除(和替代),然后是工程控制、行政控制,最后是个人防护设备(PPE)。

目的

评估非医疗相关工作场所的干预措施降低 SARS-CoV-2 感染风险的效果和危害,与其他干预措施或不干预相比。

检索方法

我们检索了 MEDLINE、Embase、Web of Science、Cochrane COVID-19 研究注册中心、加拿大职业健康与安全中心(CCOHS)、Clinicaltrials.gov 和国际临床试验注册平台,检索时间截至 2021 年 9 月 14 日。我们将每六个月更新一次本综述。

选择标准

我们纳入了随机对照试验(RCT)和计划纳入干预措施的非随机研究。我们纳入了成年工人,包括那些与客户或顾客密切接触的工人(如面向公众的员工,如收银员或出租车司机),以及那些不接触客户但可能被同事感染的工人。我们排除了涉及医护人员的研究。我们纳入了任何旨在预防或减少工人在工作场所接触 SARS-CoV-2 的干预措施,根据危害控制的层次结构对干预措施进行分类,即消除;工程控制;行政控制;个人防护设备。

数据收集和分析

我们使用了标准的 Cochrane 方法。我们的主要结局是 SARS-CoV-2 感染(或其他呼吸道病毒)的发病率、SARS-CoV-2 相关死亡率、不良事件和旷工。我们的次要结局是全因死亡率、生活质量、住院治疗以及策略的采用、可接受性或依从性。我们使用 Cochrane RoB 2 工具评估偏倚风险,使用 GRADE 方法评估每个结局的证据确定性。

主要结果

消除暴露的干预措施 我们纳入了一项研究一种干预措施的试验,该干预措施侧重于消除危害。这项研究是一项在 2021 年于英格兰进行的开放标签、整群随机、非劣效性试验。该试验比较了接触感染者后 10 天的标准自我隔离与每天快速抗原检测并在检测结果阴性时继续工作(基于检测的出勤)的新策略。试验者假设这将导致相似的感染率,但 COVID 相关缺勤率较低。在 76 所学校工作的员工(N=11798 人)被分配到标准隔离组,在 86 所学校工作的员工(N=12229 人)被分配到基于检测的出勤策略组。基于检测的出勤与标准 10 天自我隔离的结果对于有症状的 PCR 阳性 SARS-COV-2 感染率比值(RR 1.28,95%置信区间(CI)0.74 至 2.21;1 项研究,极低确定性证据)))没有定论。基于检测的出勤与标准 10 天自我隔离的结果对于任何 PCR 阳性 SARS-COV-2 感染(RR 1.35,95%置信区间(CI)0.82 至 2.21;1 项研究,极低确定性证据)))没有定论。对照组的缺勤率为 3704 天,566502 天的风险(每 1000 天风险 6.5 天),干预组为 2932 天,539805 天的风险(每 1000 天风险 5.4 天)(RR 0.83;95%置信区间 0.55 至 1.25)。由于不精确,证据的确定性被降级为低。干预组的参与率为 71%,但对照组的参与率未报告。该试验没有测量其他结局,如 SARS-CoV-2 相关死亡率、不良事件、全因死亡率、生活质量和住院治疗。我们发现了一项正在进行的关于学校筛查的 RCT,该研究使用消除危害策略。个人防护设备 我们发现了一项正在进行的关于闭合式面罩预防 COVID-19 传播效果的非随机研究。其他干预措施类别 我们没有发现其他干预措施类别的研究。

作者结论

我们不确定基于检测的出勤政策与标准的 10 天自我隔离相比,是否会影响学校和学院工作人员的 PCR 阳性 SARS-CoV-2 感染率(任何感染;有症状感染)。与标准的 10 天自我隔离相比,基于检测的出勤政策可能对缺勤率没有影响或影响很小。由于在大流行的情况下,大部分人群都暴露了,因此即使从个体角度来看,这种相对效果很小且不值得,从企业或社会角度来看,它可能仍然会产生许多人的重要绝对效果。纳入的研究没有报告我们审查的任何其他主要结局,即 SARS-CoV-2 相关死亡率和不良事件。没有发现关于本综述中规定的任何其他干预措施的已完成研究,但有两项合格研究正在进行中。需要更多的对照研究来评估检测和隔离策略以及在家工作,因为这些对工作组织有重要影响。

相似文献

3
Measures implemented in the school setting to contain the COVID-19 pandemic.学校为控制 COVID-19 疫情而采取的措施。
Cochrane Database Syst Rev. 2022 Jan 17;1(1):CD015029. doi: 10.1002/14651858.CD015029.
4
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.用于治疗 COVID-19 的 SARS-CoV-2 中和单克隆抗体。
Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.
5
Antibiotics for the treatment of COVID-19.治疗 COVID-19 的抗生素。
Cochrane Database Syst Rev. 2021 Oct 22;10(10):CD015025. doi: 10.1002/14651858.CD015025.
7
Colchicine for the treatment of COVID-19.秋水仙碱治疗 COVID-19。
Cochrane Database Syst Rev. 2021 Oct 18;10(10):CD015045. doi: 10.1002/14651858.CD015045.
8
Inhaled corticosteroids for the treatment of COVID-19.吸入性皮质类固醇治疗 COVID-19。
Cochrane Database Syst Rev. 2022 Mar 9;3(3):CD015125. doi: 10.1002/14651858.CD015125.
9
Ivermectin for preventing and treating COVID-19.伊维菌素预防和治疗 COVID-19。
Cochrane Database Syst Rev. 2022 Jun 21;6(6):CD015017. doi: 10.1002/14651858.CD015017.pub3.
10
Anticoagulants for people hospitalised with COVID-19.COVID-19 住院患者的抗凝治疗。
Cochrane Database Syst Rev. 2022 Mar 4;3(3):CD013739. doi: 10.1002/14651858.CD013739.pub2.

引用本文的文献

本文引用的文献

10
Update in COVID-19 2020.2020年新型冠状病毒肺炎的最新情况
Am J Respir Crit Care Med. 2021 Jun 15;203(12):1462-1471. doi: 10.1164/rccm.202102-0415UP.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验